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A B S T R A C T
Purpose
To compare the efficacy of four cycles of paclitaxel–bleomycin, etoposide, and cisplatin (T-BEP) to four
cycles of bleomycin, etoposide, and cisplatin (BEP) in previously untreated patients with intermediate-
prognosis germ-cell cancer (GCC).
Patients and Methods
Patients were randomly assigned to receive either T-BEP or standard BEP. Patients assigned
to the T-BEP group received paclitaxel 175 mg/m2 in a 3-hour infusion. Patients who were
administered T-BEP received primary granulocyte colony-stimulating factor (G-CSF) prophy-
laxis. The study was designed as a randomized open-label phase II/III study. To show a 10%
improvement in 3-year progression-free survival (PFS), the study aimed to recruit 498 patients
but closed with 337 patients as a result of slow accrual.
Results
Accrual was from November 1998 to April 2009. A total of 169patients were administered BEP, and 168
patients were administered T-BEP. Thirteen patients in both arms were ineligible, mainly as a result of a
good prognosis of GCC (eight patients administered BEP; six patients administered T-BEP) or a poor
prognosis of GCC (one patient administered BEP; four patients administered T-BEP). PFS at 3 years (intent
to treat) was 79.4% in the T-BEP group versus 71.1% in the BEP group (hazard ratio [HR], 0.73; CI, 0.47 to
1.13; P [log-rank test]  0.153). PFS at 3 years in all eligible patients was 82.7% versus 70.1%, respectively
(HR, 0.60; CI: 0.37 to 0.97) and was statistically significant (P  0.03). Overall survival was not
statistically different.
Conclusion
T-BEP administered with G-CSF seems to be a safe and effective treatment regimen for patients
with intermediate-prognosis GCC. However, the study recruited a smaller-than-planned number of
patients and included 7.7% ineligible patients. The primary analysis of the trial could not
demonstrate statistical superiority of T-BEP for PFS. When ineligible patients were excluded, the
analysis of all eligible patients demonstrated a 12% superior 3-year PFS with T-BEP, which was
statistically significant.
J Clin Oncol 30:792-799. © 2012 by American Society of Clinical Oncology
INTRODUCTION
The treatment of metastatic germ-cell cancer
(GCC) with cisplatin-etoposide based chemo-
therapy results in the cure of the majority of
patients.1 In the current consensus classification
for nonseminoma and seminoma, the following
three prognostic categories are defined; a good-
prognosis group with a 5-year disease-free sur-
vival (DFS) of 90%, an intermediate-prognosis
group with a 5-year DFS of 70%, and a poor-
prognosis group with a 5-year DFS of 45%.2 For all
three prognostic groups, the administration of bleo-
mycin, etoposide, and cisplatin (BEP) is the stan-
dard treatment.
Three decades of chemotherapy studies that
tested shortened intervals between chemotherapy
cycles, the concept of alternating or sequential
chemotherapy,andrecentstudiesofhigh-dosechem-
otherapy plus autologous peripheral stem-cell sup-
port have not proven to be superior to the gold
standard of BEP.3-5
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An alternative strategy could be the incorporation of a new
effective agent in the BEP regimen. Paclitaxel has demonstrated
activity in two phase II studies in patients with platinum-refractory
cancer.6,7 Therefore, the European Organisation for Research and
Treatment of Cancer (EORTC) decided to investigate the addition
of paclitaxel to BEP. In a formal paclitaxel (Taxol; Bristol-Myers
Squibb International, Brussels, Belgium)– bleomycin, etoposide,
and cisplatin (T-BEP) dose-finding study, paclitaxel was adminis-
tered at dose levels of 75, 125, 175, and 200 mg/m2 in a 3-hour
infusion on day 1 before the start of BEP.8 Primary granulocyte
colony-stimulating factor (G-CSF) prophylaxis was applied. A
dose of paclitaxel 175 mg/m2 was feasible with full-dose BEP, and
this regimen was chosen for the intended randomized multi-
center study.
The randomized phase II/III study of T-BEP versus BEP in pa-
tients with intermediate-prognosis GCC reported in this article was
conducted in the framework of EORTC, the German Testicular Can-
cer Study Group/Association of Urologic Oncology, the Medical Re-
search Council (Testis Cancer study 21)/United Kingdom National
Cancer Research Institute Testicular Cancer Clinical Study Group,
and the Spanish Germ-Cell Cancer Group.
PATIENTS AND METHODS
Patients
Patients were eligible for the study if they had intermediate-prognosis
metastatic GCC according to International Germ Cell Cancer Concensus
as follows: for nonseminoma, all of (1) a testis or retroperitoneal primary
tumor, (2) -fetoprotein (AFP)  1,000 but  10,000 U/L, human chori-
onic gonadotropin  5,000 U/L (1,000 ng/mL) but  50,000 U/L (10,000
ng/mL), or lactate dehydrogenase  1.5 but  10 the upper limit of
normal, and (3) no liver, bone, brain, or other nonpulmonary visceral
metastases; and for pure seminoma, (1) any primary site, (2) any lactate
dehydrogenase and any human chorionic gonadotropin, (3) nonpulmo-
nary visceral metastases present, and (4) AFP within the normal range.
Patients were not accepted if they had previously received chemotherapy,
had a creatinine clearance less than 40 mL/min, or were less than 16 or
greater than 50 years of age. All patients provided ethics board– approved
written informed consent.
Treatment
Standard BEP consisted of cisplatin 20 mg/m2 days 1 through 5 and
etoposide 100 mg/m2 administered days 1 through 5 for four cycles. Bleomy-
cin was administered at a dose of 30 mg weekly for 12 weeks (total dose of
bleomycin, 360 mg). Patients administered T-BEP received paclitaxel 175
mg/m2 given as a 3-hour infusion on day 1, before starting standard BEP, for
four cycles. Paclitaxel was supplied by Bristol-Myers Squibb International.
G-CSF (filgrastim and later pegfilgrastim) was used for primary prophylaxes in
patients allocated to the T-BEP group. In patients who received BEP, G-CSF
was used only as secondary prophylaxis.
Chemotherapy dose modifications for hematologic toxicity are pre-
sented in detail in Appendix Tables A1 and A2 (online only).
After grade 3 or 4 mucosal toxicity or diarrhea, the following cycle of
chemotherapy was delayed until recovery. For patients allocated to the
T-BEP group, the dose of paclitaxel was reduced by 25% for all remaining
cycles. For clinically significant hypersensitivity reactions during paclitaxel
administration, the infusion was discontinued, and patients were treated
with antihistamines and epinephrine and were retreated at the discretion of
the investigator.
The actual dose-intensity was calculated as follows for all drugs except





Actual total treatment duration (week)
The relative dose intensity (RDI) was the ratio of the observed dose
intensity to the weekly dose planned per protocol and expressed as a percent-
age. The average RDI for BEP or T-BEP was obtained by averaging the RDI of
the individual components of each regimen.
Response Assessment
After completion of chemotherapy, patients with normal tumor marker
levels and no clinical or radiologic evidence of residual masses were classified as
complete responders and were monitored without additional therapy. Patients
in whom markers normalized but who showed evidence of residual tumor
mass underwent debulking surgery unless the initial histologic diagnosis was
pure seminoma. The protocol advised complete macroscopic resection of all
tumor remnants. These patients were classified as complete responders if the
histologic examination showed no viable cancer. If viable malignancy had been
resected completely, patients were classified as having been rendered disease
free by chemotherapy plus surgery. Patients in whom the surgical resection of
residual viable cancer was incomplete, patients who had a continuing increase
of tumor markers, or patients who had disease progression while receiving
chemotherapy or within 2 months after the completion of chemotherapy were
classified as incomplete responders. Rising tumor markers or an increase in
tumor volume (unless this was caused by mature teratoma that was completely
resectable) was considered progression of disease. Patients with residual
masses who did not undergo complete debulking surgery were classified as
nonassessable for response and included in progression-free survival (PFS)
and survival analyses. Events in the PFS analysis were incomplete response,
progression of disease, and death.
Sample Size and Statistical Analysis
The study was designed as an open-label phase II/III trial. Phase II
aimed at the exclusion of a complete-response (CR) rate of 65% (one-sided
  0.10; power, 95%) with a two-stage optimum Simon design. A maxi-
mum of 82 patients taking T-BEP were needed, with the assumption that
the true CR rate was 80%. Phase III was planned to show an increase of the
3-year PFS from 75% to 85% with T-BEP (hazard ratio [HR], 0.56) with
80% power and am two-sided   0.05. To this aim, 98 events were
needed, and it was planned to recruit 498 patients. Randomization was by
minimization to ensure the treatment arms were balanced with respect to
histology (seminoma v nonseminoma or combined tumors) and the num-
ber of patients allocated in each hospital.9,10
The decision to continue the trial into phase III was taken by the EORTC
independent data monitoring committee in March 2004. In December 2006,
the EORTC independent data monitoring committee requested and reviewed
an interim analysis of the phase III trial by using stopping rules for both futility
(-family with   2) and superiority (-family with   3),11 but the
boundaries were not crossed, and the study continued. The trial eventually
closed to accrual in August 2009 with 337 patients as a result of recruitment
problems and difficulties with paclitaxel supply. An independent statistician
advised to conduct the final analysis when a minimum of 2 years follow-up was
reached for all patients entered before June 2008. With 85 events of PFS
observed in the intent-to-treat population, the study had a power of 74%
(instead of 80% as planned) to detect the hypothesized difference in PFS if it
was present. The CIs of the 3-year PFS rates in both treatment groups were
compatible with the hypothesized values (ie, 75% and 85%).
The primary analysis of the response rate was in all eligible patients;
patients of PFS and overall survival were in the intent-to-treat population.
Sensitivity analyses were conducted in eligible patients and eligible patients
who started the allocated treatment (per-protocol population). Survival end
points were described by Kaplan-Meier curves, and comparisons were ana-
lyzed by using the nonstratified log-rank test. Binary variables were compared
by using the 2 test. The analysis was based on all available data as of January 3,
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2011. All tests were two-sided at the 5% significance level with adjustment for
the interim analysis (nominal   0.0455).
RESULTS
A total of 337 patients from 12 countries entered the trial between
November 1998 and April 2009; 169 patients were allocated to the BEP
group, and 168 patients were allocated to the T-BEP group.
Of these patients, 26 patients were found ineligible (mostly as a
result of a different prognostic classification), and for six patients, the
eligibility was not completely verifiable (Fig 1). Of importance, distri-
butions of good-risk and poor-risk ineligible patients were uneven
because there were numerically more good-risk patients (predestined
for a better prognosis) in the standard BEP-treatment group, whereas
four of five poor-risk patients (with the associated worse prognosis)
had been allocated to the T-BEP group.
Besides the 26 ineligible patients, the following five additional
patients were excluded from the per-protocol analysis: one patient in
the T-BEP group who received BEP instead and four eligible patients
without documented treatment (one patient taking BEP and three
patients taking T-BEP).
As of the clinical cutoff date of January 3, 2011, the median
follow-up of all patients was 5.3 years. There was no difference in
follow-up between the two treatment groups.
The pretreatment characteristics of all patients are listed in Table
1. The two treatment arms were well balanced with respect to age,
histology, and disease extent, with the exception of a higher median
AFP in the T-BEP arm (499 IU/L in the T-BEP group v 156 IU/L in the
BEP group; Kruskal-Wallis P  .0350).
Treatment Administered
In the intent-to-treat population, 92.3% of patients allocated to
the BEP group completed four cycles of treatment; in patients allo-
cated to the T-BEP group, 87.5% of patients completed four cycles of
treatment. In the safety population (all patients who started the allo-
cated treatment) these percentages were 96.3% and 91.3%, respec-
tively. The reasons not to receive the allocated four cycles were mostly
due to ineligibility, toxicity (including three patients with allergic
reactions to paclitaxel), and refusal.
In the safety population, the median average RDI achieved for all
agents was 97.1% in the BEP group and 97.5% in the T-BEP group.
Detailed information about the dose intensity and RDI for each com-
ponent in the two study arms is shown in Appendix Tables A3 and A4
(online only). In patients treated with BEP, 26% of patients had at least
one cycle postponed, mainly as a result of hematologic toxicity; in
patients who received T-BEP, 16% of patients had at least one cycle
postponed, likely as a result of the primary use of G-CSF, as per
Eligible
(n = 153) 
ITT population, PFS (n = 48 of 169)
Per-protocol population, PFS (n = 44 of 152)
ITT population, deaths (n = 19 of 169)
Per-protocol population, deaths (n = 17 of 152)
)961 = n( TTI yb dezylanA
Per-protocol analysis (n = 152)
ITT population, PFS (n = 37 of 168)
Per-protocol population, PFS (n = 28 of 148)
ITT population, deaths (n = 17 of 168)
Per-protocol population, deaths (n = 10 of 148)
)861 = n( TTI yb dezylanA




  BEP (n = 152)
  Not treated (n = 1)
Per-protocol population: 
  T-BEP (n = 148)
  BEP (n = 1)
  Not treated (n = 3)
ITT population:
BEP (n = 169)
ITT population:
T-BEP (n = 168)
Eligible
(n = 152) 
T-BEP (n = 13)
Not treated (n = 3)
Not treated (n = 1)
Ineligible (n = 13)
  Good risk (IGCCCG) (n = 8)
  Poor risk (IGCCCG) (n = 1)
  Prior treatment (n = 2)
  Insufficient proof of (n = 2)
    GCC/other cancer
No baseline data (n = 3)
Ineligible (n = 13)
  Good risk (IGCCCG) (n = 6)
  Poor risk (IGCCCG) (n = 4)
  Prior treatment (n = 0)
  Insufficient proof of (n = 3)
    GCC/other cancer
No baseline data (n = 3)
BEP (n = 9)
T-BEP (n = 1)
Not treated (n = 6)
Fig 1. CONSORT diagram. BEP, bleo-
mycin, etoposide, and cisplatin; GCC,
germ-cell cancer; IGCCCG, International
Germ Cell Cancer Collaborative Group;
ITT, intent to treat; PFS, progression-
free survival; T-BEP, paclitaxel– bleomy-
cin, etoposide, and cisplatin.
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protocol. In patients who received BEP, G-CSF was applied during at
least one cycle in 33% of patients.
Toxicity
Dose reductions were applied at least once in 15% of patients
who received BEP and in 12% of patients who received T-BEP. How-
ever, 9.3% of patients who received BEP compared with 22% of
patients who received T-BEP stopped one drug definitively (mostly
bleomycin as a result of pulmonary toxicity [eight patients in each
arm] or paclitaxel as a result of allergic reactions, refusal, or reclassifi-
cation into good-prognosis disease). Grade 3 and 4 neutropenia was
encountered more frequently during BEP treatment, which was most
likely caused by the restrictive use of G-CSF for secondary prophylaxis
only, whereas patients who received T-BEP received G-CSF for pri-
mary prophylaxis. However, there were numerically more neutro-
penic fevers in the T-BEP group than in the BEP group (19% versus
10%, respectively; Table 2). Grades 2 and 3 mucositis/stomatitis and
diarrhea occurred more frequently in the T-BEP group. However,
grade 4 toxicities were rare in both study arms (Table 2).
There were seven fatal adverse events. Of these, four events
were possibly related to treatment; two patients (one patient who










Leucocytes  1.0  10 g/L 17 10.6 26 16.1
Leucocytopenic fever 16 10 31 19.2
Platelets  25  10 g/L 5 3.1 5 3.1
Nonhematologic toxicity
Allergic reaction
Grades 1-2† 15 9.3 30 18.6
Grades 3-4 0 0 9 5.5
Fatigue
Grades 1-2 111 69 103 64
Grades 3-4 4 2.5 12 7.5
Stomatitis/mucocitis
Grades 1-2 57 35.4 72 44.7
Grades 3-4 4 2.5 15 9.4
Diarrhea
Grades 1-2 32 19.9 56 34.8
Grades 3-4 3 1.9 16 9.9
Sensory neuropathy
Grades 1-2 46 28.5 57 35.4
Grades 3-4 2 1.2 0 0
Other neurotoxicity
Grades 1-2 23 14.3 24 14.9
Grades 3-4 3 1.2 1 0.6
Nausea
Grades 1-2 117 72.7 114 70.8
Grades 3-4 7 4.3 11 6.8
Abbreviations: BEP, bleomycin, etoposide, and cisplatin; T-BEP, paclitaxel–
bleomycin, etoposide, and cisplatin.
Leucocytes  2.0  10 g/L, temperature  38°C.
†Denotes National Cancer Institute Common Toxicity Criteria version 2.0,
worst toxicity reported over all cycles.















Interquartile range 23-35 24-35
Disease characteristic
Histology
Seminoma 14 8.3 15 8.9
Non seminoma 108 63.9 103 61.3
Combined seminoma and
nonseminoma 44 26.0 46 27.4
Unknown/missing 3 1.8 4 2.4
Primary site
Testis 156 92.3 155 92.3
Retroperitoneal 10 5.9 8 4.8
Mediastinal 1 0.6 2 1.2
Other/missing 2 1.2 3 1.8
Involved metastatic sites
Abdominal lymph nodes 147 86.9 144 85.8
Mediastinal lymph nodes 46 27.3 52 30.9
Supraclavicular lymph
nodes 25 14.8 22 13.1
Lung metastases 81 47.9 86 51.2
Liver metastases 3 1.8 4 2.4
Bone metastases 3 1.8 7 4.2
AFP, IU/L
 1,000 117 69.2 91 54.2
1000  AFP  10,000 50 29.6 74 44.0
 10,000 0 0.0 1 0.6





 5,000 119 70.4 116 69.0
5,000  HCG  50,000 48 28.4 49 29.2
50,000 0 0.0 1 0.6





 1.5 ULN 44 26.0 57 33.9
1.5 ULN  LDH
 10 ULN 121 71.6 107 63.7
 10 ULN 2 1.2 2 1.2




Abbreviations: AFP, -fetoprotein; BEP, bleomycin, etoposide, and cisplatin;
HCG, human chorionic gonadotropin; LDH, lactate dehydrogenase; Q, quartile;
T-BEP, paclitaxel–bleomycin, etoposide, and cisplatin; ULN, upper limit
of normal.
2 test for different distribution of AFP ( 1,000 v  1000 ng/mL), P  .005;
Kruskall-Wallis 2 test for difference in distribution of actual AFP values,
P  .035.
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pulmonary embolism between cycles 1 and 2, one patient who
received T-BEP died from pulmonary fibrosis that was likely bleo-
mycin related, and one patient developed diarrhea and fever dur-
ing his first cycle of T-BEP, was admitted 2 days later at a nearby
hospital, and died during the diagnostic workup from sudden
cardiorespiratory failure. The remaining three fatal events were not
treatment related.
Post-Treatment Evaluations and Surgery
After chemotherapy, the majority of patients in both treat-
ment arms had residual lesions (135 patients [80.4%] who received
T-BEP versus 134patients (79.3%) who received BEP). Reasons not
to resect all lesions, as reported by the investigators on the forms,
were mostly due to either multiple lesions or lesions resected at one
site that contained no vital cancer, and the decision was made not
to resect additional lesions (detailed information is listed in Ap-
pendix Tables A5 to A7; online only). Histology was obtained from
119 patients with nonseminoma or mixed seminoma/nonsemi-
noma histologies who received T-BEP and from 116 patients who
received BEP. Complete resection of all remnants was possible in
50.8% of the patients who received T-BEP and underwent surgery
and in 48.8% of patients who received BEP. Viable cancer was
found in nine patients (7%) who received T-BEP and in 15 patients
(12.9%) who received BEP.
Response to Treatment
Responses to chemotherapy, with or without surgery, were com-
puted primarily in eligible patients. Because 4.5% of eligible patients
did not start the allocated treatment, a computation was also made for
eligible patients who started allocated treatment (per-protocol analy-
sis). Analyses of intent to treat, all eligible patients, and per-protocol
are listed in Table 3. In the eligible patient population, the rate of
CR/no evidence of disease after chemotherapy plus surgery rate was
70.4% in the T-BEP group versus 59.5% in the BEP group (P .0549).




No. of Patients % No. of Patients % No. of Patients %
Intent-to-treat analysis
No. of patients 169 168 337
Response to treatment
CR to chemotherapy only 84 49.7 100 59.5 184 54.6
NED, CR after chemotherapy and surgery 11 6.5 8 4.8 19 5.6
Treatment failure 17 10.1 7 4.2 24 7.1
Not evaluable 56 33.1 47 28.0 103 30.6
Early death as a result of disease 1 0.6 2 1.2 3 0.9
Early death as a result of toxicity 0 0.0 2 1.2 2 0.6
Early death as a result of other reason 0 0.0 2 1.2 2 0.6
Response, CR/NED 95 56.2 108 64.3 203 60.2
95% CI, % 48.4 to 63.8 56.5 to 71.5 P  .1482
All eligible patients
No. of patients 153 152 305
Response to treatment
CR to chemotherapy only 80 52.3 99 65.1 179 58.7
NED, CR after chemotherapy and surgery) 11 7.2 8 5.3 19 6.2
Treatment failure 15 9.8 5 3.3 20 6.6
Not evaluable 46 30.1 36 23.7 82 26.9
Early death as a result of disease 1 0.7 1 0.7 2 0.7
Early death as a result of toxicity 0 0.0 2 1.3 2 0.7
Early death as a result of other 0 0.0 1 0.7 1 0.3
Response, CR/NED 91 59.5 107 70.4 198 64.9
95% CI, % 51.2 to 67.3 62.4 to 77.5 P  .0549
Per-protocol analysis
No. of patients 152 148 300
Response to treatment
CR to chemotherapy only 80 52.6 98 66.2 178 59.3
NED, CR after chemotherapy and surgery 11 7.2 8 5.4 19 6.3
Treatment failure 15 9.9 5 3.4 20 6.7
Not evaluable 45 29.6 34 23.0 79 26.3
Early death as a result of disease 1 0.7 1 0.7 2 0.7
Early death as a result of toxicity 0 0.0 2 1.4 2 0.7
Response, CR/NED 91 59.9 106 71.6 197 65.7
95% CI, % 51.6 to 67.7 63.6 to 78.7 P  .0384
Abbreviations: BEP, bleomycin, etoposide, and cisplatin; CR, complete response; NED, no evidence of disease; T-BEP, paclitaxel–bleomycin, etoposide,
and cisplatin.
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In eligible patients who actually started the allocated treatment
(per-protocol population), the response rate (CR/no evidence of
disease) was 71.6% in the T-BEP group versus 59.9% in the BEP
group (P  .0384).
PFS and Survival
PFS and survival are listed in Table 4. In the intent-to-treat
population (including all ineligible patients as well as the patients who
did not start the allocated chemotherapy), the 3-year PFS rate was
79.4% in the T-BEP group and 71.1% in the BEP group. PFS curves
were not statistically significant (HR, 0.73; CI, 0.47 to 1.13; P  .153;
Table 4; Fig 2). With the exclusion of the 26 (7.7%) ineligible patients,
3-year PFS rates were 82.7% versus 70.1%, respectively (HR, 0.60; CI,
0.37 to 0.97, P  .0307). The difference was significant at the adjusted
0.0455 significance level. This may have been due to the fact that
ineligible patients were more often ineligible as a result of having
poor-risk GCC in the T-BEP arm and, vice versa, having good-risk
GCC in the BEP arm. Moreover, most ineligible patients were treated
outside of the protocol (good prognosis with BEP). In addition, one
patient in each arm received the opposite treatment. With the addi-
tional exclusion of the five patients who did not receive the allocated
treatment (per-protocol analysis), 3-year PFS rates were 83.2 versus
70.6%, respectively (HR, 0.59; CI, 0.37 to 0.96; P  .0289), similar to
the results in eligible patients. Both the PFS analysis in all eligible
patients and the per-protocol analysis showed a 12% superior 3-year
PFS with T-BEP.
With only 36 events in the intent-to-treat population and 27
events in the per-protocol analysis, differences in overall survival were
not statistically significant (HR, 0.89; CI, 0.46 to 1.74; P  .7382 in the
intent-to-treat population; HR, 0.58; CI, 0.26 to 1.29; P  .1700 in the
per-protocol analysis (Table 4; Fig 3). Adjustment of the comparisons
for the baseline AFP values that were imbalanced between groups did
not change these results (Table 4).
DISCUSSION
Recent studies of upfront high-dose chemotherapy or dose-
intensified etoposide, ifosfamide, and cisplatin chemotherapy in
poor-risk GCC have not demonstrated superiority over the stan-
dard BEP treatment.4,5 In view of the activity of paclitaxel in the
second-line treatment setting in phase 2 studies6,7 the EORTC
and other collaborative groups in Europe decided to investigate
the addition of paclitaxel to standard BEP in patients with
intermediate-risk GCC. The T-BEP dose-finding study showed
that the regimen was generally well tolerated, and with the use of
primary G-CSF prophylaxis, a dose of paclitaxel 175 mg/m2 was
feasible with standard-dose BEP8
This study was designed as a randomized open-label phase
II/III study. The study originally aimed to recruit 498 patients. The
enrollment onto the study was hampered by logistical problems,
including delays in trial initiation in some countries that were
anticipated to recruit a large proportion of the total patient group.
When paclitaxel finally became generic, and multiple brands be-
came available for use in the European countries, the regulatory
burden associated with amending the protocol as well as the cessa-
tion of a free-drug supply further reduced the accrual and resulted
in the decision by the EORTC to stop the trial with 337 patients
randomly assigned.












95% CI % 95.45% CI
PFS
Intent to treat, primary analysis
BEP 169 48 0.73 0.47 to 1.13 .1531 71.08 63.14 to 77.61
T-BEP 168 37 0.70† 0.44 to 1.10† .1113† 79.43 72.12 to 85.02
All eligible
BEP 153 45 0.60 0.37 to 0.97 .0307 70.13 61.82 to 76.98
T-BEP 152 29 0.56† 0.35 to 0.92† .0181† 82.69 75.28 to 88.06
Per protocol
BEP 152 44 0.59 0.37 to 0.96 .0289 70.63 62.32 to 77.45
T-BEP 148 28 0.55† 0.34 to 0.91† .0166† 83.16 75.75 to 88.48
Survival
Intent to treat, primary analysis
BEP 169 19 0.89 0.46 to 1.74 .7382 89.83 83.78 to 93.70
T-BEP 168 17 0.88† 0.44 to 1.75† .7137† 91.23 85.48 to 94.77
All eligible
BEP 153 17 0.64 0.30 to 1.39 .2501 89.72 83.37 to 93.74
T-BEP 152 11 0.64† 0.29 to 1.41† .2618† 94.42 88.99 to 97.21
Per protocol
BEP 152 17 0.58 0.26 to 1.29 .1700 89.65 83.26 to 93.69
T-BEP 148 10 0.57† 0.25 to 1.29† .1698† 95.04 89.71 to 97.64
Abbreviations: BEP, bleomycin, etoposide, and cisplatin; PFS, progression-free survival; T-BEP, paclitaxel bleomycin, etoposide, and cisplatin.
To be compared with the adjusted .0455 significance level.
†Cox models with adjustment for baseline -fetoprotein.
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Fig 2. Progression-free survival (A) in intent-to-treat population; (B) for all eligible
patients; (C) in the per-protocol population. O, observed events.
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Fig 3. Overall survival (A) in the intent-to-treat population; (B) for all eligible
patients; and (C) in the per-protocol population. O, observed events.
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The primary efficacy analysis (intent to treat) conducted with 85 of
98 events of PFS planned by design had only a 74% power of demonstrat-
ing statistical superiority of T-BEP if the hypothesized treatment effect
(HR, 0.56) was present. However, extrapolation of the results obtained in
the intent-to-treat population (HR, 0.73) to a hypothetical full-sample
size of 98 events would not have reached conventional statistical signifi-
cance with a theoretical 95% CI for the HR that ranged from 0.49 to 1.01.
The intent-to-treat results were confounded by 13 ineligible pa-
tients in each arm (8%) with an unfortunate uneven distribution
among the two treatment groups with more good-prognosis patients
allocated to the BEP group, most of whom were eventually treated
outside of the protocol, and more (four of five) poor-prognosis pa-
tients allocated to the T-BEP group. This uneven distribution of inel-
igibles with the associated different prognostic outcome (good
prognosis with BEP and poor prognosis with T-BEP) may have biased
the results toward the null hypothesis of no difference. Also, for vari-
ous reasons, several eligible patients (one patient who received BEP
and three patients who received T-BEP) did not start the allocated
treatment or received the opposite treatment.
The PFS at 3 years (intent to treat) was 79.4% in the T-BEP group
versus 71.1% in the BEP group (HR, 0.73; P .153). However, the PFS
for the eligible patient population was 82.7% versus 70.1%, respec-
tively (HR, 0.60; P  .03). This difference reached the adjusted level of
statistical significance, as did the analysis in the per-protocol popula-
tion. Both analyses showed a 12% superior PFS at 3 years. Numeri-
cally, these observed differences at 3 years were in the order of
magnitude of what was anticipated (10%). As could be expected in the
setting of GCC, with salvage regimens available and a low number of
events, the overall survival was not statistically different.
This trial failed to demonstrate the superior efficacy of T-BEP in
the management of the intended intermediate-prognosis GCC risk
population on the basis of its primary analysis. However, the eligible-
patient analysis as well as the per-protocol analysis that were thought
to alleviate the conservative bias induced by the uneven distribution of
ineligible or untreated patients that dragged the results toward the null
hypothesis of no difference both reached statistical significance. With
a small number of events, survival was not statistically significantly differ-
ent between the two groups. The T-BEP regimen with the use of primary
G-CSFprophylaxiswasgenerallywell toleratedwithonlytwotoxicdeaths
(1%) in the framework of this large multicenter study. The study showed
a favorable toxicity profile of T-BEP in patients with intermediate-
prognosis GCC. Whether or not T-BEP has a potential benefit in the
poor-risk GCC patient category remains to be determined because this
patient group was not planned to be recruited in the study.
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